NeuBase Therapeutics (NBSE) Stock on November 23, 2025: Delisting, Liquidation Escrow and What Shareholders Still Need to Know
NeuBase Therapeutics stock is one of those tickers that still pops up on certain quote screens in late 2025 – but in reality, it isn’t a “normal” stock anymore. As of Sunday, November 23, 2025, NeuBase is a dissolved biotech in legal wind‑down, its common shares delisted and largely cashed out through liquidation payments and a non‑tradable escrow structure. MarketWatch+1 Below is a deep, investor‑focused look at what NBSE actually represents today, what happened in 2024–2025, and what, if anything, existing shareholders can still reasonably expect. Key takeaways for NBSE on November 23, 2025 Where NeuBase stands today (Sunday, November
